JP2005537234A5 - - Google Patents

Download PDF

Info

Publication number
JP2005537234A5
JP2005537234A5 JP2004508829A JP2004508829A JP2005537234A5 JP 2005537234 A5 JP2005537234 A5 JP 2005537234A5 JP 2004508829 A JP2004508829 A JP 2004508829A JP 2004508829 A JP2004508829 A JP 2004508829A JP 2005537234 A5 JP2005537234 A5 JP 2005537234A5
Authority
JP
Japan
Prior art keywords
chlorotoxin
temozolomide
derivative
therapeutic agent
cancer therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004508829A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005537234A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/017410 external-priority patent/WO2003101474A1/en
Publication of JP2005537234A publication Critical patent/JP2005537234A/ja
Publication of JP2005537234A5 publication Critical patent/JP2005537234A5/ja
Pending legal-status Critical Current

Links

JP2004508829A 2002-05-31 2003-06-02 クロロトキシンとの併用化学療法 Pending JP2005537234A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38417102P 2002-05-31 2002-05-31
US40603302P 2002-08-27 2002-08-27
PCT/US2003/017410 WO2003101474A1 (en) 2002-05-31 2003-06-02 Combination chemotherapy with chlorotoxin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011052039A Division JP5856744B2 (ja) 2002-05-31 2011-03-09 クロロトキシンとの併用化学療法

Publications (2)

Publication Number Publication Date
JP2005537234A JP2005537234A (ja) 2005-12-08
JP2005537234A5 true JP2005537234A5 (https=) 2010-02-04

Family

ID=29715313

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2004508829A Pending JP2005537234A (ja) 2002-05-31 2003-06-02 クロロトキシンとの併用化学療法
JP2011052039A Expired - Lifetime JP5856744B2 (ja) 2002-05-31 2011-03-09 クロロトキシンとの併用化学療法
JP2015134259A Pending JP2015214562A (ja) 2002-05-31 2015-07-03 クロロトキシンとの併用化学療法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2011052039A Expired - Lifetime JP5856744B2 (ja) 2002-05-31 2011-03-09 クロロトキシンとの併用化学療法
JP2015134259A Pending JP2015214562A (ja) 2002-05-31 2015-07-03 クロロトキシンとの併用化学療法

Country Status (10)

Country Link
US (1) US20060166892A1 (https=)
EP (4) EP2182004A1 (https=)
JP (3) JP2005537234A (https=)
AT (1) ATE458751T1 (https=)
AU (2) AU2003237347B2 (https=)
CA (2) CA2494451A1 (https=)
DE (1) DE60331458D1 (https=)
ES (1) ES2341767T3 (https=)
MX (1) MXPA04011871A (https=)
WO (2) WO2003101474A1 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060088899A1 (en) * 2002-05-31 2006-04-27 Alvarez Vernon L Combination chemotherapy with chlorotoxin
WO2005053611A2 (en) * 2003-11-26 2005-06-16 Transmolecular, Inc. Treatment of phosphatidylinositol phospholipid disorders
AU2005232616A1 (en) * 2004-04-06 2005-10-27 Transmolecular, Inc. Diagnosis and treatment of myeloid and lymphoid cell cancers
DE602006020710D1 (de) 2005-04-22 2011-04-28 Fred Hutchinson Cancer Res Foundation Fluoreszentes chlorotoxinkonjugat und verfahren zur intraoperativen sichtbarmachung von krebs
CA2647907A1 (en) * 2006-03-31 2007-10-18 Transmolecular, Inc. Use of tm-601 for the diagnosis and treatment of tumors
US8106013B2 (en) 2006-05-19 2012-01-31 Georgia Tech Research Corporation ABC transporter ligand GATX1
CN100590130C (zh) * 2007-07-31 2010-02-17 厦门北大之路生物工程有限公司 抗癌活性肽
EP2173385A1 (en) * 2007-08-07 2010-04-14 Transmolecular, Inc. Chlorotoxins as drug carriers
US20100215575A1 (en) * 2007-10-12 2010-08-26 Transmolecular, Inc. Systemic Administration of Chlorotoxin Agents for the Diagnosis and Treatment of Tumors
CN102438646A (zh) * 2008-05-15 2012-05-02 特兰斯莫莱库拉公司 转移性肿瘤的治疗
CA2724384A1 (en) 2008-05-15 2009-11-19 Transmolecular, Inc. Treatment of metastatic tumors
WO2010086964A1 (ja) * 2009-01-28 2010-08-05 株式会社 静岡カフェイン工業所 がん治療のための併用療法
CN102844044B (zh) 2010-02-04 2016-10-26 摩尔弗泰克有限公司 氯毒素多肽和结合物及其应用
EP3165533B1 (en) 2010-05-11 2020-04-08 Fred Hutchinson Cancer Research Center Chlorotoxin variants, conjugates and methods for their use
CU24055B1 (es) * 2010-09-27 2014-12-26 Grupo Empresarial De Producciones Biofarmacéuticas Y Químicas Labiofam Composiciones farmacéuticas de veneno de escorpión rhopalurus junceus
GB201106004D0 (en) 2011-04-08 2011-05-25 Univ Edinburgh Optical imaging probes
WO2013003507A1 (en) 2011-06-27 2013-01-03 Morphotek, Inc. Multifunctional agents
KR20150050524A (ko) 2012-04-17 2015-05-08 메리맥 파마슈티컬즈, 인크. 비침습적 이미징을 위한 조성물 및 방법
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
CA2913029A1 (en) 2012-12-10 2014-06-19 Fred Hutchinson Cancer Research Center Lipocalin fusion partners
EP2986287A2 (en) * 2013-04-18 2016-02-24 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and pharmaceutical compositions (ctps 1 inhibitors, e.g. norleucine) for inhibiting t cell proliferation in a subject in need thereof
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
WO2015061592A1 (en) * 2013-10-23 2015-04-30 Merrimack Pharmaceuticals, Inc. Liposomes for non-invasive imaging and drug delivery
US9522114B1 (en) * 2014-03-27 2016-12-20 University Of South Florida Enhanced targeted drug delivery system via chitosan hydrogel and chlorotoxin
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
JP7042739B2 (ja) 2015-08-20 2022-03-28 イプセン バイオファーム リミティド 癌処置のためのリポソーム型イリノテカン及びparp阻害薬を使用する併用療法
TW202400181A (zh) 2015-08-21 2024-01-01 英商益普生生物製藥有限公司 使用包含微脂伊立替康(irinotecan)及奧沙利鉑(oxaliplatin)之組合療法治療轉移性胰臟癌的方法
WO2017143259A1 (en) * 2016-02-19 2017-08-24 Dignity Health Antibody fusion protein and related compositions for targeting cancer
US12048732B2 (en) 2016-04-15 2024-07-30 Blaze Bioscience, Inc. Methods of treating breast cancer
KR101678393B1 (ko) 2016-08-25 2016-12-06 (주)넥스젠바이오텍 피부 세포 증식 효과가 증가한 전갈독 융합단백질 및 이를 유효성분으로 함유하는 피부 주름 개선, 피부 탄력 증대 및 항노화 화장료 조성물
CN110402163A (zh) 2016-11-02 2019-11-01 易普森生物制药有限公司 使用包括脂质体伊立替康、奥沙利铂、5-氟尿嘧啶(和甲酰四氢叶酸)的组合疗法治疗胃癌
CN111542345B (zh) 2017-09-15 2025-02-25 卫材公司 氯毒素剂及其用途
CA3086040A1 (en) 2017-12-19 2019-06-27 Blaze Bioscience, Inc. Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0491007B1 (en) * 1989-09-08 1996-03-13 The Johns Hopkins University Structural alterations of the egf receptor gene in human gliomas
US5223253A (en) * 1989-09-28 1993-06-29 American Home Products Corporation Bovine vaccine compositions and method for preventing trichomonas infections using same
US5750376A (en) * 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
EP0922458A1 (en) * 1993-01-14 1999-06-16 Cancer Research Campaign Technology Limited Potentiation of temozolomide by an ATase inhibitor
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5756340A (en) * 1995-05-08 1998-05-26 The Regents Of The University Of California Insect control with multiple toxins
JP3809502B2 (ja) * 1995-05-30 2006-08-16 二郎 有川 ハンタウィルス抗原蛋白質およびモノクローナル抗体
JPH0971599A (ja) * 1995-09-06 1997-03-18 Nippon Seibutsu Kagaku Kenkyusho 鶏貧血ウイルス(cav)感染鶏血清と高い反応性を示すポリペプチド及びこのポリペプチドに対する抗体、鶏貧血ウイルス感染の診断法及びワクチン
US5905027A (en) * 1995-12-27 1999-05-18 Uab Research Foundation Method of diagnosing and treating gliomas
US6667156B2 (en) * 1995-12-27 2003-12-23 Uab Research Foundation Diagnosis and treatment of neuroectodermal tumors
US6555652B1 (en) * 1997-12-05 2003-04-29 Kyogo Itoh Tumor antigen peptide derivatives

Similar Documents

Publication Publication Date Title
JP2005537234A5 (https=)
GB0211649D0 (en) Organic compounds
WO2003096989A3 (en) Anti tubercular drug: compositions and methods
JP2006501240A5 (https=)
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
MXPA03010402A (es) Derivados de 4-amino-5-fenil-7-ciclobutil-pirrolo (2,3-d) pirimidina.
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
SE0100568D0 (sv) Compounds
EA200301165A1 (ru) Лекарственное средство на основе оксикодона
JP2004534850A5 (https=)
WO2007044085A3 (en) Heteroaryl compounds and their uses as therapeutic agents
JP2008505857A5 (https=)
NZ542866A (en) Compositions and methods for the therapy of inflammatory bowel disease
SE0100566D0 (sv) Compounds
YU68702A (sh) Novi lhrh-antagonisti, njihova proizvodnja i upotreba kao leka
JP2009500045A5 (https=)
DE60320034D1 (de) Behandlung von mastitis mit einer kombination aus prednisolon und cephalosporin
WO2005034857A3 (en) Methods and compositions comprising diamines as new anti-tubercular therapeutics
PL357999A1 (en) Lhrh-antagonists, production and use thereof as medicament
WO2006125178A3 (en) Tricyclic pyridazine compounds and their uses as therapeutic agents
SE0101692D0 (sv) Compounds
MX2009006670A (es) Composicion farmaceutica que usa el aliskiren y el avosentan.
JP2007517775A5 (https=)
CA2469702A1 (en) Darifenacin for use in the treatment of urgency induced by overactive bladder
PT1572686E (pt) Derivados de amida do ácido antranílico e suas utilizações farmacêuticas